FDA Clearance Tracker · DEN210046
Quell-FM
Last checked: Nov 20, 2026Latest source record: May 18, 2022 (this decision)Source: openFDAMethods & limitations
Decided
May 18, 2022
De Novo granted
Time to decision
225 days
Received Oct 5, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
De Novo
Direct
Device class
Class II
The decision
- FDA number
- DEN210046
- Device name
- Quell-FM
- Applicant
- Neurometrix, Inc.
- Applicant location
- Woburn, MA
- Received
- Oct 5, 2021
- Decided
- May 18, 2022
- Decision
- De Novo granted
- Submission type
- Direct
Device type
- Device class
- Class II
- Regulation
- 21 CFR 882.5888
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
- It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).
Source documents
- FDA database record for DEN210046
- Decision summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
Other decisions for Neurometrix, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Quell510(k)
K152954 · Decided Jan 5, 2016 · 90 days after receipt
Device type: Stimulator, Nerve, Transcutaneous, Over-The-Counter (NUH) · Neurology & Neurosurgery
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.